@article{d1daa5407c2440c1b37140b4340c1e14,
title = "Melanoma, version 2.2016 clinical practice guidelines in oncology",
abstract = "This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.",
author = "Coit, {Daniel G.} and Thompson, {John A.} and Alain Algazi and Robert Andtbacka and Bichakjian, {Christopher K.} and Carson, {William E.} and Daniels, {Gregory A.} and Dominick DiMaio and Marc Ernstoff and Fields, {Ryan C.} and Fleming, {Martin D.} and Rene Gonzalez and Valerie Guild and Halpern, {Allan C.} and Hodi, {F. Stephen} and Joseph, {Richard W.} and Lange, {Julie R.} and Martini, {Mary C.} and Materin, {Miguel A.} and Olszanski, {Anthony J.} and Ross, {Merrick I.} and Salama, {April K.} and Joseph Skitzki and Jeff Sosman and Swetter, {Susan M.} and Tanabe, {Kenneth K.} and Torres-Roca, {Javier F.} and Vijay Trisal and Urist, {Marshall M.} and Nicole McMillian and Anita Engh",
note = "Publisher Copyright: {\textcopyright} 2016 National Comprehensive Cancer Network, Inc.",
year = "2016",
month = apr,
day = "1",
doi = "10.6004/jnccn.2016.0051",
language = "English (US)",
volume = "14",
pages = "450--473",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Harborside Press",
number = "4",
}